CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 107 enrolled
Drug / intervention
Ablation Therapy +3 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04083378
NCT04083378Phase 2Active

Clinical Impact of a Volumetric Image Method for Confirming Tumor Coverage With Ablation on Patients With Malignant Liver Lesions (COVER-ALL)

M.D. Anderson Cancer Center·interventional·Posted Sep 10, 2019·Updated Mar 23, 2026

In Brief

A Phase 2 clinical trial evaluating Ablation Therapy, Image-Guided Therapy, and 2 other interventions for Malignant Liver Neoplasm. Active but no longer recruiting, targeting 107 participants across 1 site.

Detailed Summary

This phase II trial studies how well software-aided imaging works in confirming tumor coverage with ablation (the removal or destruction of a body part or tissue or its function) on patients with liver tumors. The current standard for targeting tumor cells and evaluating the outcome of a liver ablation procedure is a visual inspection of the pre- and post-procedure computed tomography (CT) scans. Software-aided imaging systems, such as Morfeus, may help to improve the accuracy and effectiveness of liver ablation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedSep 10, 2019
Enrollment StartJan 10, 2020
Primary CompletionOct 31, 2024
Study CompletionOct 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.8 years ago

Interventions

Ablation Therapyprocedure

Undergo standard of care ablation

Image-Guided Therapyprocedure

Undergo software-aided imaging (Morfeus)

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies